Síntese e atividade biológica do derivado 6-formil-oxamniquina

Almeida, Adélia Emília de; Souza, Ana Luiza Ribeiro de; Allegretti, Silmara Marques; Frezza, Tarsila Ferraz; Pinto, Mara Cristina; Ferreira, Antônio G.; Chin, Chung Man

doi:10.1590/s1516-93322008000400022

Cited by 2 publications

(3 citation statements)

References 10 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[93,94] Oxidation of the hydroxymethyl group leads to 6-formyl-oxamniquine (17,F igure 3D), which has asimilar antischistosomal activity.This is explained by the re-reduction of the aldehyde either by human or parasite reductases. [95] The other major metabolites of 13 (18 and 19,F igure 3D)p resented no negative effects. Less than 2% of the administered dose is excreted in urine as unchanged drug.…”

Section: Oxamniquinementioning

confidence: 94%

“…C) Oxamniquine ( 13 ) and its mechanism of action . D) Chemical structures of 6‐formyl‐oxamniquine ( 17 ) and metabolites ( 18 and 19 ) of oxamniquine …”

Section: Anthelmintic Drug Therapymentioning

confidence: 99%

“…[91,92] D) Chemical structures of 6-formyl-oxamniquine (17)a nd metabolites (18 and 19)o fo xamniquine. [95,96] Structure-activity relationship (SAR) studies on miracil A( 11, Figure 3B)l ed to UK-3883( 12,F igure 3B), the development of which by Pfizer resulted in OXA (13). [89,90] OXA is ap rodrug that is sulfonated by ap arasite sulfotransferase (SULT) using 3'phosphoadenosine 5'-phosphosulfate (PAPS) as an active substrate.…”

Section: Oxamniquinementioning

confidence: 99%

See 2 more Smart Citations

Chemotherapy for Fighting Schistosomiasis: Past, Present and Future

et al. 2018

View full text Add to dashboard Cite

Chemotherapy based on repeated doses of praziquantel remains the most effective control strategy against schistosomiasis, a neglected tropical disease caused by platyhelminths of the genus Schistosoma spp. Its long-term use, however, raises serious concerns about drug resistance against praziquantel. Therefore, it is generally acknowledged that alternative treatment options are urgently needed. This Review summarizes data on relinquished drugs as well as recent advances in the area of antischistosomal compounds from a medicinal chemistry point of view. Furthermore, insights into the structure-activity relationships of each class of compounds are presented including in vitro and in vivo data, if available. Although many compounds have demonstrated good antischistosomal activity in vitro, they offer little promise to replace praziquantel. Nevertheless, the race to develop novel antischistosomal agents is ongoing.

show abstract

Section: Oxamniquinementioning

confidence: 94%

“…C) Oxamniquine ( 13 ) and its mechanism of action . D) Chemical structures of 6‐formyl‐oxamniquine ( 17 ) and metabolites ( 18 and 19 ) of oxamniquine …”

Section: Anthelmintic Drug Therapymentioning

confidence: 99%